CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Enoxaparin +1 moredrug
Likely dose
Enoxaparin 1 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01763606
NCT01763606N/ACompleted
CompareCT.gov

A Pilot Trial of Enoxaparin Versus Aspirin in Patients With Cancer and Stroke

Memorial Sloan Kettering Cancer Center·interventional·Posted Jan 9, 2013·Updated Aug 14, 2020

In Brief

A clinical study evaluating Enoxaparin and Aspirin for Cancer Patients First-ever Acute Ischemic Stroke. Completed, enrolled 20 participants across 7 sites.

Detailed Summary

Patients with cancer who develop stroke are at high risk for future strokes or other clotting events. These patients are routinely treated with medicines that thin their blood, including enoxaparin or aspirin. However, it is unclear which medicine is best and whether these medicines can be adequately studied in a clinical trial. The purpose of this Phase I/II study is to determine if a clinical trial of different blood thinners in patients with cancer and stroke is possible. In addition, the study aims to compare the effects, good and/or bad, of enoxaparin with those of aspirin on patients with cancer and recent stroke.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer Patients First-ever Acute Ischemic Stroke
CountriesUnited States
CollaboratorsNew York Presbyterian Hospital, Weill Medical College of Cornell University

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 9, 2013
Enrollment StartDec 18, 2012
Primary CompletionApr 3, 2019
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 13.5 years ago

Interventions

Enoxaparindrug

Patients will be receive 6 months of subcutaneous enoxaparin (1 mg/kg BID with a maximum starting dose of 100 mg BID. Patients who weigh more than 100 kg will start at a dose of 100 mg BID; their subsequent dosing will be guided by hematology and may change.

Aspirindrug

Patients will receive 6 months of oral aspirin (81 mg per day unless a higher dose is preferred by study physicians although the maximum acceptable dose will be 325 mg per day).